

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): August 3, 2020

Neoleukin Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36327
(Commission
File Number)

98-0542593
(IRS Employer
Identification No.)

**360-1616 Eastlake Avenue East
Seattle, Washington 98102**
(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (206) 732-2133

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.000001 par value	NLTX	The Nasdaq Global Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure

On August 3, 2020, Neoleukin Therapeutics, Inc., “Neoleukin” submitted a manuscript to bioRxiv, titled “De novo design of ACE2 protein decoys to neutralize SARS-CoV-2”. BioRxiv is an online archive for unpublished preprints in the life sciences. The manuscript details the creation of a de novo protein decoy that binds to the SARS-CoV-2 spike protein and neutralizes viral infection of mammalian cells in vitro. The research was conducted by Neoleukin scientists and colleagues at the University of Hong Kong, University of Washington and University of North Carolina at Chapel Hill. The manuscript is currently undergoing peer review. Once posted, the manuscript will be available at [bioRxiv.org](https://www.biorxiv.org/).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOLEUKIN THERAPEUTICS, INC.

Date: August 3, 2020

By: /s/ Robert Ho

Robert Ho

Chief Financial Officer